相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A rapid α-synuclein seed assay of Parkinson's disease CSF panel shows high diagnostic accuracy
Christina D. Orru et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study
Alex Iranzo et al.
LANCET NEUROLOGY (2021)
High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease
Marco J. Russo et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2021)
Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes
Corinne Quadalti et al.
NPJ PARKINSONS DISEASE (2021)
RT-QuIC Detection of Pathological α-Synuclein in Skin Punches of Patients with Lewy Body Disease
Angela Mammana et al.
MOVEMENT DISORDERS (2021)
Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort
Nour K. Majbour et al.
MOVEMENT DISORDERS (2021)
Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies
Marcello Rossi et al.
NEUROLOGY (2021)
RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies
Ilaria Poggiolini et al.
BIOMOLECULES (2021)
Diagnostic Value of the CSF a-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies
Marcello Rossi et al.
NEUROLOGY (2021)
Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies
Marcello Rossi et al.
ACTA NEUROPATHOLOGICA (2020)
CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers
Nour K. Majbour et al.
TRANSLATIONAL NEURODEGENERATION (2020)
Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets
Somin Kwon et al.
NEUROTHERAPEUTICS (2020)
Update on the diagnosis and management of Parkinson's disease
Christopher Kobylecki
CLINICAL MEDICINE (2020)
Safety and immunogenicity of the α-synuclein active immunotherapeutic PDO1A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
Dieter Volc et al.
LANCET NEUROLOGY (2020)
α-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease
Alicia Garrido et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Parkinson's disease biomarkers based on α-synuclein
Muneera Fayyad et al.
JOURNAL OF NEUROCHEMISTRY (2019)
CSF and blood biomarkers for Parkinson's disease
Lucilla Parnetti et al.
LANCET NEUROLOGY (2019)
Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease
N. N. Vaikath et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2019)
Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC
Bradley R. Groveman et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
Inger van Steenoven et al.
MOVEMENT DISORDERS (2018)
Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid
Mohammad Shahnawaz et al.
JAMA NEUROLOGY (2017)
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease
Nour K. Majbour et al.
MOLECULAR NEURODEGENERATION (2016)
Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression
Nour K. Majbour et al.
MOVEMENT DISORDERS (2016)
Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies
Graham Fairfoul et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
MDS clinical diagnostic criteria for Parkinson's disease
Ronald B. Postuma et al.
MOVEMENT DISORDERS (2015)
Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology
Nishant N. Vaikath et al.
NEUROBIOLOGY OF DISEASE (2015)
Rapid and Sensitive RT-QuIC Detection of Human Creutzfeldt-Jakob Disease Using Cerebrospinal Fluid
Christina D. Orru et al.
MBIO (2015)
Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity
K. D. van Dijk et al.
EUROPEAN JOURNAL OF NEUROLOGY (2014)
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease
Oskar Hansson et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
Jan O. Aasly et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
Lucilla Parnetti et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
α-Synuclein oligomers and clinical implications for Parkinson disease
Lorraine V. Kalia et al.
ANNALS OF NEUROLOGY (2013)
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
Brit Mollenhauer et al.
NEUROSCIENCE LETTERS (2013)
Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
Sara Hall et al.
ARCHIVES OF NEUROLOGY (2012)
Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naive Patients with Parkinson's Disease
Min Jeong Park et al.
JOURNAL OF CLINICAL NEUROLOGY (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study (vol 10, pg 230, 2011)
B. Mollenhauer et al.
LANCET NEUROLOGY (2011)
Cerebrospinal Fluid Tau/α-Synuclein Ratio in Parkinson's Disease and Degenerative Dementias
Lucilla Parnetti et al.
MOVEMENT DISORDERS (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
Brit Mollenhauer et al.
LANCET NEUROLOGY (2011)
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease
Zhen Hong et al.
BRAIN (2010)
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
T. Tokuda et al.
NEUROLOGY (2010)
Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
Lucilla Parnetti et al.
BIOLOGICAL PSYCHIATRY (2008)
Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
Brit Mollenhauer et al.
EXPERIMENTAL NEUROLOGY (2008)
Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease
Omar M. A. El-Agnaf et al.
FASEB JOURNAL (2006)
Clinical features of LRRK2-associated Parkinson's disease in Central Norway
JO Aasly et al.
ANNALS OF NEUROLOGY (2005)
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
MS Forman et al.
NATURE MEDICINE (2004)
Molecular pathways to neurodegeneration
E Bossy-Wetzel et al.
NATURE MEDICINE (2004)
Macular microcirculation characteristics in Parkinson's disease evaluated by OCT-Angiography: a literature review
Evita Evangelia Christou et al.
SEMINARS IN OPHTHALMOLOGY
分享论文
